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Dear Sir:
We have read with great interest a recent article by Dr. He et al. in the June issue of
Gastroenterology.1 The studies provide strong evidence in favor of the concept that smooth
muscle–specific myosin phosphatase target subunit 1 (MYPT1) of myosin light chain
phosphatase (MLCP) plays a critical role in the agonist-induced contraction/relaxation of the
smooth muscle. This was shown in their studies using animals with knocked out MYPT1-/-. The
investigators employed the Cre-loxP system in which they used the promoter region and exon 1
of Mypt1 flanked by 2 loxP sites to establish Mypt1-floxed mice. These mice were crossed with
SMA-Cre transgenic mice to generate smooth muscle–specific MYPT1 knockout mice
(Mypt1SMKO).
The authors demonstrated that the phasic responses (to acetylcholine, ACh and K+depolarization) of the jejunal and ileal smooth muscles of the mutant mice in comparison with
the control mice are converted into a tonic type with sustained force. The converted responses
had reduced rates of shortening velocity and relaxation because of higher levels of phosphoMLC20 (p-MLC20). The authors observed no apparent abnormality in the intestinal motility in
the mutant mice, although there was a definite trend towards the decrease in the intestinal transit
(a predicted effect). The lack of statistical significance for the abnormal intestinal motility may
have been because of the huge variability among the mutant mice reflected by 49.9 ± 13.9 SEM
% transit values. The issue of intestinal motility abnormality in the Mypt1SMKO may be resolved
by studying a larger number of animals with a group beyond 16-week old, and by detailed
examinations of the entire gut from the esophagus to the anorectum. The present studies had
primarily focused on the limited regions of the gastrointestinal tract.
Critical role of MYPT1 in the sustained contraction has been previously demonstrated in the
phenotypically tonic vs. the phasic smooth muscles of the gastrointestinal tract, in the basal
state.2,3 Additionally, there appear to be certain similarities between Mypt1SMKO animals and the
spontaneously hypertensive rats: an increase in blood pressure and in the intestinal smooth
muscle contractility with a corresponding decrease in MYPT1.1,4,5 An increase in the
neurotransmitter (ACh)-mediated amplitude and sustained contraction of the intestinal smooth
muscle in MYPT1SMKO is suggestive of dysfunctional smooth muscle typified in the diffuse
esophageal spasm in response to swallowing. It has been proposed that defective inhibitory
neurotransmission mediated by nitric oxide (NO) and vasoactive intestinal polypeptide (VIP),
unopposed excitatory neurotransmitters’ (ACh; substance P, SP) contractile actions, and
increased smooth muscle sensitivity may be responsible for the uncoordinated often hypertensive
contractions, failure of the descending inhibition, and achalasic/hypertensive sphincteric smooth
muscles.6
Present data with the higher sensitivity of the smooth muscle in response to the excitatory
agonists in the presence of similar concentrations of intracellular Ca2+, suggest the role of Ca2+sensitization via inhibition of MLCP via MYPT1, the primary target for RhoA/ROCK. Also,
there are studies to show significantly higher levels of endogenous inhibitory protein CPI-17
(originally named so because of its targeting PKC, protein-kinase C potentiated inhibitor) in the
tonic vs. phasic smooth muscles. Recently, it is becoming evident that RhoA/ROCK contributes
to Ca2+ sensitization not only by targeting MYPT1 but also by targeting CPI-17, so that CPI-17
is not exclusively targeted by PKC.3,7 Data from humans and animals show significantly higher
levels of CPI-17 in the spontaneously tonic smooth muscle vs. the phasic, and specific decreases
in the phospho-CPI-17 following selective RhoA/ROCK inhibitors. The bimodal effect of

RhoA/ROCK on MYPT1 and CPI-17 however was not appropriately discussed in the paper by
He et al.
In view of a critical role of MLCK/MYPT1-MLCP/p-MLC20 in the smooth muscle
relaxation/contraction, it is important to determine the significance of MYPT1 in the regionspecific pathophysiology in response to the corresponding reflexes, e.g. swallowing in the case
of esophagus, and rectoanal inhibitory (defecation) reflex in the anorectum. In this regard, the
potential of MYPT1 gene-deleted animal models similar to that of Mypt1SMKO (but without
compensatory genetic and adaptive physiologic responses) may go beyond the investigation of
the molecular mechanisms for the agonist-induced smooth muscle contraction. Such molecular
insights may further reveal the pathophysiology of certain motility disorders, with or without
characteristic dysfunctional inhibitory and excitatory neurotransmissions as discussed before.6
These disorders may involve MYPT1-associated deranged signal transduction cascade for the
smooth muscle contraction/relaxation to explain disturbed changes in the latency gradient for the
sequential contractions, a hall mark for the normal progression of the food and ingesta leading to
the expulsion of the waste.8

References
1.
2.
3.
4.
5.
6.
7.
8.

He W-Q, et al. Gastroenterology 2013;144:1456-1465.
Rattan S, et al. Gastroenterology 2010;138:13-18.
Patel CA, et al. Am J Physiol Gastrointest Liver Physiol 2006;291:G830-G837.
De Godoy MAF, et al. J Pharmacol Exp Ther 2006;318:725-734.
De Godoy MA, et al. Gastroenterology 2013;143:A.
Goyal RK, et al. Gastroenterology 2010;139:1086-1090.
Rattan S, et al. Am J Physiol Gastrointest Liver Physiol 2012;302:G664-G675.
Sanders KM, et al. Nat Rev Gastroenterol Hepatol 2012;9:633-645.

